Semaglutide Linked to NAION Risk

• by Andrea Surnit

• May 11, 2026

FDA clears targeted cholangiocarcinoma therapy

In the single-arm REFOCUS trial, 46% of patients responded to treatment, with a median response duration of 11.8 months.

• by Kathryn Wighton

• September 24, 2026

• 2 min

Retinal Age Model Tied to Disease Risk

Fundus-based tool estimates biologic aging but shows modest gains over prior models

• by Andrea Surnit

• May 1, 2026

• 4 min

Brolucizumab in the Treatment of Proliferative Diabetic Retinopathy: The CONDOR Randomized Clinical Trial

• by Sebastian Wolf, Youxin Chen, Xiaorong Li, Masahiko Shimura, Taiji Sakamoto, Charles C. Wykoff, Andres Emanuelli, Hani Salehi-Had, Kang Yan, Lidija Kovacic, Yongsoo Kim

• June 1, 2026